NMT Medical Inc.
27 Wormwood street
Boston,
MA 02210-1625
Phone: 617-737-0930
Fax: 617-737-0924
Web Site: http://www.nmtmedical.com
| REUTERS ABRIDGED BUSINESS SUMMARY | |
| NMT Medical, Inc., a medical technology company, designs, develops, manufactures, and markets implant technologies that allow interventional cardiologists to treat structural heart disease through minimally invasive catheter-based procedures. Its products primarily include CardioSEAL, a cardiac septal repair implant device used for the repair of structural heart disease and intracardiac shunts that result in abnormal blood flow through the chambers of the heart; STARFlex, which incorporates a self-centering system that allows the implant to self-adjust to variations in the anatomy of a septal defect without deforming the septum or interfering with heart valve function; and BioSTAR, a bioabsorbable PFO implant and biological closure technology. The company also develops BioTREK, a biological closure technology, which incorporates a biosynthetic material that uses the bodys own regenerative capability to restore function naturally. Its customers include hospitals, clinics, and other healthcare centers. The company markets its products through distributors, as well as directly in the United States, Canada, Europe, and internationally. NMT Medical, Inc. was founded in 1986 and is headquartered in Boston, Massachusetts. |
|
| Key Statistics | More from Reuters
Expanded Business Description |
| |
| REUTERS ABRIDGED FINANCIAL SUMMARY | |
| | Pay | Exercised | Mr. Frank Martin , 73
Chief Exec. Officer, Pres |
$
41.00K | N/A | Mr. Richard E. Davis , 52
Chief Operating Officer, Chief Financial Officer, Principal Accounting Officer, Exec. VP, Sec. |
$
359.00K |
$
0 | Mr. Brad Ryno ,
VP of Worldwide Sales |
N/A
| N/A | Mr. Geoff Fournie ,
VP of Clinical Devel. -Europe |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.03 (1.48%)
Reuters offers more in-depth
